至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Mutations in the mitochondrial ribosomal protein MRPS22 lead to primary ovarian insufficiency.

Hum. Mol. Genet.. 2018; 
ChenAnlu,TiosanoDov,GuranTulay,BarisHagit N,BayramYavuz,MoryAdi,Shapiro-KulnaneLaura,HodgesCraig A,AkdemirZeynep C,TuranSerap,JhangianiShalini N,van den AkkerFocco,HoppelCharles L,SalzHelen K,LupskiJames R,BuchnerDav
Products/Services Used Details Operation
DNA Sequencing The 12 PCR amplicons that were not covered by WES in Family I on chromosome 3 between rs2737735 and rs16850488 were amplified and sequenced with the primers listed in Table S2. Sanger sequencing was performed by GenScript. Get A Quote

摘要

Primary ovarian insufficiency (POI) is characterized by amenorrhea and loss or dysfunction of ovarian follicles prior to the age of 40. POI has been associated with autosomal recessive mutations in genes involving hormonal signaling and folliculogenesis, however, the genetic etiology of POI most often remains unknown. Here we report MRPS22 homozygous missense variants c.404G>A (p.R135Q) and c.605G>A (p.R202H) identified in four females from two independent consanguineous families as a novel genetic cause of POI in adolescents. Both missense mutations identified in MRPS22 are rare, occurred in highly evolutionarily conserved residues, and are predicted to be deleterious to protein function. In contrast t... More

关键词